Synonyms: ANG-3070 | ANG3070 | Example 1 [WO2013112959A1]
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for ansornitinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase kinase inhibitor. Ansornitinib may be ANG-3070, an oral tyrosine kinase inhibitor that was developed by Angion Biomedica for anti-fibrotic potential in kidney diseases, such as focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Clinical trial of ANG-3070 was terminated in June 2022, following an unexpected and dangerous decline in kidney function in a patient who received the drug treatment. Development for idiopathic pulmonary fibrosis appears to be continuing.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
methyl 2-hydroxy-3-[N-[4-[methyl-[2-(4-methylpiperazin-1-yl)acetyl]amino]phenyl]-C-phenylcarbonimidoyl]-1H-pyrrolo[2,3-b]pyridine-6-carboxylate |
International Nonproprietary Names ![]() |
|
INN number | INN |
12287 | ansornitinib |
Synonyms ![]() |
ANG-3070 | ANG3070 | Example 1 [WO2013112959A1] |
Database Links ![]() |
|
CAS Registry No. | 1448874-96-1 (source: WHO INN record) |
GtoPdb PubChem SID | 472319208 |
PubChem CID | 136234633 |
Search Google for chemical match using the InChIKey | OABALTWKAJWHEA-RQZHXJHFSA-N |
Search Google for chemicals with the same backbone | OABALTWKAJWHEA |
Search PubMed clinical trials | ansornitinib |
Search PubMed titles | ansornitinib |
Search PubMed titles/abstracts | ansornitinib |
UniChem Compound Search for chemical match using the InChIKey | OABALTWKAJWHEA-RQZHXJHFSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | OABALTWKAJWHEA-RQZHXJHFSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Ansornitinib (links to external site)
Cat. No. HY-147243 |